Evaluating the Impact of a Novel Cannabinoid Product for Endometriosis

Recruiting now · Phase 2 · Has a placebo group

Conditions studied: Endometriosis

In brief

Despite the proliferation of cannabis and cannabinoid products in recent years, little research has been done to determine the impact of these products on womens health conditions, including endometriosis. This study is designed to assess the impact of a custom-formulated, hemp-derived, full-spectrum, high-CBD product vs. placebo on clinical symptoms and biomarkers over the course of 12 weeks of treatment in patients with endometriosis. This project will provide information that does not currently exist on the potential efficacy of a cannabinoid-based sublingual product for endometriosis.

Key facts

Study ID
NCT06477406
Run by
Mclean Hospital
People needed
30
Starts
2024-02-27
Expected to finish
2026-10-01
Last updated by the study team
2026-07-21

Who can join

Age: 21 and older. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.